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A 68 kDa (pl= 7.3) nuclear phosphoprotein has been previously characterized as a component of transcriptionally active 
chromatin. Two-dimensional PAGE Western blotting and radioimmunoassay with monoclonal antibodies have identified 
this protein in nuclear extracts used for in vitro RNA splicing. In vitro splicing activity could be quantitatively inhibited 
by preincubating nuclear extracts with the antibodies, but the assembly of 60 S spliceosomes could not. 
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1. INTRODUCTION 
Nonhistone nuclear proteins have been widely 
studied for their potential role in gene regulation 
(see reviews [l-3]). A nuclear phosphoprotein has 
been previously identified within operationally 
defined transcriptionally-active chromatin and 
shown to become more abundant following 16 h of 
liver regeneration [4-61. This purified protein has 
been used for preparing monoclonal antibodies 
[7]. Using these antibodies for two-dimensional 
PAGE Western blotting, this phosphoprotein was 
also identified among proteins which comprise the 
operationally defined nuclear matrix fraction [8]. 
Moreover, electron microscopy of immunogold- 
labeled thin sections revealed a preponderance of 
this nuclear protein in the vicinity of the nuclear 
envelope [9]. From these data, the phosphoprotein 
has been proposed to have a role in transcriptional 
or posttranscriptional processes. 
In this report, we present data which 
demonstrate the presence of the phosphoprotein in 
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nuclear extracts used for in vitro RNA splicing and 
show that monoclonal antibodies specific for this 
protein inhibit the ability of the extracts to carry 
out RNA splicing. 
2. MATERIALS AND METHODS 
Nuclear extracts were prepared from spinner culture HeLa 
cells grown to mid log phase in RPM1 1640 media containing 
10% fetal calf serum essentially as described by Dignam et al. 
[lo]. Modifications included triethanolamine (TEO), pH 7.9, as 
a buffer, dithiothreitol (DTT) was omitted, and 1 mM 
phenylmethanesulphonyl fluoride (PMSF), 0.05 ,ug/tnl leupep- 
tin and aprotinin and 20 U/ml soybean trypsin inhibitors were 
included in all buffers. Protein concentrations of the extracts 
averaged 6 mg/ml. 
In vitro RNA splicing reactions were carried out under op- 
timized conditions [ll] with SP-6 adenovirus late-leader se- 
quence single intron (IVS) transcripts [12,13] as splicing 
precursors. The IVS substrate (456 nucleotides) contained the 
natural first and second exons of the adenovirus late transcrip- 
tion unit separated by a shortened intron. Sliceosome assembly 
was determined by electrophoresing one-fifth of each in vitro 
splicing reaction into native, low porosity agarose-acrylamide 
composite gels [ 141. 
Characterization of monoclonal antibodies and the radioim- 
munoassay were as described previously [7]. Western blotting 
conditions were also described previously [8,15] and utilized 
‘251-protein A and autoradiographic detection system. 
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Fig. 1. Nuclear extract proteins (80 pg) were resolved on two- 
dimensional gels, transferred to nitrocellulose and reacted with 
IgC& monoclonal antibody against he nuclear phosphoprotein 
(1:200 dilution). The M, distribution and pH gradient are 
shown to the left and bottom of the figure, respectively. 
3. RESULTS 
Two-dimensional PAGE of nuclear extract pro- 
teins followed by Western blotting with anti- 
phosphoprotein IgGza monoclonal antibody 
revealed the presence of an antigen with appro- 
priate size and isoelectric point, 68 kDa and pl = 
7.3, respectively (fig. 1). Radioimmunoassays con- 
firmed these findings and demonstrated saturable 
(and therefore specific) antigen-antibody binding 
(table 1). 
Nuclear extracts preincubated with IgGza 
monoclonal antibody on ice for 30 min were no 
longer competent for in vitro RNA splicing com- 
pared to controls (fig.2). Monoclonal antibodies 
Table 1 
Monoclonal antibody Nuclear extract &g) Bound cpm 
Nonimmune IgG 1 309 
10 176 
50 252 
Immune Ig& 1 794 
1 794 
10 1453 
50 2300 
Nonimmune IgG represents the tissue culture fluid. IgC& is the 
monoclonal antibody of a nuclear phosphoprotein. 
Radioimmunoassay was carried out by using a goat anti-mouse 
Ig-‘251 
Fig.2. RNA was purified from in vitro splicing reactions, 
resolved by PAGE and autoradiographed. Radiolabeled RNAs 
corresponding to the splicing-precursor (premRNA), 
intermediate products intron-exon 2 (E21) and exon 1 (El), and 
products intron (I), exon I-exon 2 (ElE2) are shown to the 
right. Lanes 1 and 2 correspond to control splicing reaction at 
time zero and after 60 min of incubation, respectively. Lanes 
3-6 are all 60 min incubations which had been pretreated with 
2 ~1 of native antibody, 2 ~1 of heat-inactivated antibody, 10 ~1 
of native antibody, and 10~1 of heat-inactivated antibody, 
respectively. 
reactive with UsnRNA common or unique proteins 
also inhibited splicing activity in the extract (data 
not shown and [21]). Boiling of the antibodies for 
3 min prior to their addition to the extract 
uniformly prevented the antibody inhibition of 
RNA splicing. These findings suggest that the an- 
tibody effect was specific and that the 
phosphoprotein might have a role in RNA pro- 
cessing. 
In vitro RNA processing involves an ordered 
assembly of the RNA splicing-precursor into a 
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Fig.3. Ribonucleoprotein complexes within in vitro splicing 
reactions were resolved on native acrylamide-agarose g ls and 
those containing radiolabeled RNAs visualized by 
autoradiography. The position of 20 S and 60 S complexes are 
indicated to the right. Lanes 1 and 2 correspond to complexes 
seen at time zero and after 60 min of in vitro reaction, 
respectively. Lanes 3-6 are complexes seen after 60 min of 
reaction which had been pretreated with 2 ~1 of native antibody, 
2 ~1 of heat-inactivated antibody, 10 ~1 of native antibody, and 
10 gl of heat-inactivated antibody, respectively. 
60 S complex [11,14]. To determine at what stage 
in this process antibody inhibition occurred, com- 
plexes within the splicing reactions were resolved 
by native, agarose-acrylamide gel electrophoresis 
[ 141. Immediately after adding the radiolabeled 
RNA splicing-precursor to the extract, 20 S 
nonspecific complexes form, which are transform- 
ed in a time-dependent fashion into functional 
60 S spliceosomes [ 141. Addition of the 
monoclonal antibody (with or without boiling) did 
not affect this assembly process (fig.3), whereas 
anti-UsnRNP antibodies block this process at the 
20 S complex stage (data not shown and [21]). 
4. DISCUSSION 
Nonhistone nuclear proteins have been widely 
speculated upon as gene regulatory elements [l-3]. 
Monoclonal antibodies specific for a 68 kDa 
phosphoprotein [7] have been previously used to 
localize this protein within the ultrastructure of 
transcriptionally active nuclear domains 
[3-5,7-91. From these studies, it has been pro- 
posed that this nuclear phosphoprotein may be in- 
volved in the anchorage of transcriptionally active 
genes to the nuclear matrix [6] and thereby 
possibly involved in transcriptional or post- 
transcriptional nuclear processes. 
The data presented here demonstrate the 
presence of p6Wpl = 7.3 in splicing-competent 
nuclear extracts, and suggest that the protein might 
be involved in premessenger RNA processing. The 
inhibition of splicing by native and not heat- 
inactivated Ig& suggests that the data reflect 
specific interference with ~68’s function by the an- 
tibodies. The ability of 60 S spliceosome com- 
plexes to assemble in the presence of the IgG 
supports the possibility that the data are not due to 
nonspecific effects. Moreover, assembly of 60 S 
complexes which are not competent for RNA splic- 
ing suggests that p68 might be involved in splicing 
during some stage following spliceosome 
assembly. 
Proteins with molecular masses similar to the 
one described here have been reported among 
those UV cross-linkable to precursor RNA in vitro 
[ 16-181, as components of uridine-rich small 
nuclear ribonucleoprotein particles [ 191 and in- 
volved in early recognition of intervening se- 
quences [20]. Most recently, we found that 
monoclonal antibodies specific for the 70 kDa 
Ul-snRNP protein [22] failed to react the 68 kDa 
nuclear protein, which was isolated and purified 
from 2D gels (not shown), while at the same time 
the monoclonal antibody of the 68 kDa protein 
reacted strongly in a distinctive region at ~17.3 as 
shown in fig. 1. The possible relationship of these 
proteins to this nuclear protein reported here will 
be of interest in future studies. 
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